Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 9:09 pm Sale |
2023-12-31 | 13G | SCYNEXIS, Inc. SCYX |
CAXTON CORP | 0 0.000% |
-2,210,672 (Position Closed) |
Filing History |
| 2024-02-13 9:00 pm Sale |
2023-12-31 | 13G | Savara Inc. SVRA |
CAXTON CORP | 353,441 0.300% |
-6,543,110 (-94.88%) |
Filing History |
| 2023-02-14 1:27 pm Purchase |
2022-12-31 | 13G | Rezolute, Inc. RZLT |
CAXTON CORP | 1,860,518 4.990% |
527,045 (+39.52%) |
Filing History |
| 2023-02-14 12:47 pm Sale |
2022-12-31 | 13G | Cardiff Oncology, Inc. CRDF |
CAXTON CORP | 983,607 2.200% |
-2,495,733 (-71.73%) |
Filing History |
| 2023-02-14 12:30 pm Sale |
2022-12-31 | 13G | Addex Therapeutics Ltd ADXN |
CAXTON CORP | 35,942 0.900% |
-79,782 (-68.94%) |
Filing History |
| 2023-02-14 12:15 pm Sale |
2022-12-31 | 13G | Xeris Biopharma Holdings, Inc. XERS |
CAXTON CORP | 5,973,324 4.400% |
-1,856,358 (-23.71%) |
Filing History |
| 2022-02-14 4:13 pm Purchase |
2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF |
CAXTON CORP | 3,479,340 8.100% |
380,893 (+12.29%) |
Filing History |
| 2022-02-14 4:10 pm Purchase |
2021-12-31 | 13G | SCYNEXIS, Inc. SCYX |
CAXTON CORP | 2,210,672 9.000% |
736,302 (+49.94%) |
Filing History |
| 2022-02-14 4:07 pm Sale |
2021-12-31 | 13G | Addex Therapeutics Ltd ADXN |
CAXTON CORP | 115,724 6.000% |
-90 (-0.08%) |
Filing History |
| 2022-02-14 4:04 pm Purchase |
2021-12-31 | 13G | Rezolute, Inc. RZLT |
CAXTON CORP | 1,333,473 8.600% |
769,230 (+136.33%) |
Filing History |
| 2022-02-14 4:01 pm Sale |
2021-12-31 | 13G | CTI BioPharma Corp. CTIC |
CAXTON CORP | 2,239,300 2.300% |
-1,510,590 (-40.28%) |
Filing History |
| 2022-02-14 3:57 pm Sale |
2021-12-31 | 13G | Sierra Oncology, Inc. SRRA |
CAXTON CORP | 1,119,322 7.000% |
-23,039 (-2.02%) |
Filing History |
| 2022-02-14 3:52 pm Unchanged |
2021-12-31 | 13G | Savara Inc. SVRA |
CAXTON CORP | 6,896,551 6.100% |
0 (Unchanged) |
Filing History |
| 2022-01-05 12:50 pm Sale |
2021-10-05 | 13D | Strongbridge Biopharma plc SBBP |
CAXTON CORP | 0 0.000% |
-10,280,682 (Position Closed) |
Filing History |
| 2022-01-05 12:38 pm Purchase |
2021-10-05 | 13G | Xeris Biopharma Holdings, Inc. XERS |
CAXTON CORP | 7,829,682 5.700% |
7,829,682 (New Position) |
Filing History |
| 2021-03-19 4:53 pm Purchase |
2021-03-11 | 13G | Savara Inc. SVRA |
CAXTON CORP | 6,896,551 6.200% |
6,896,551 (New Position) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | Sierra Oncology, Inc. SRRA |
CAXTON CORP | 1,142,361 9.900% |
60,161 (+5.56%) |
Filing History |
| 2021-02-16 4:23 pm Sale |
2020-12-31 | 13G | CTI BioPharma Corp. CTIC |
CAXTON CORP | 3,749,890 5.100% |
-737,427 (-16.43%) |
Filing History |
| 2021-02-16 4:19 pm Purchase |
2020-12-31 | 13G | Addex Therapeutics Ltd ADXN |
CAXTON CORP | 115,815 8.400% |
115,815 (New Position) |
Filing History |
| 2021-02-16 4:06 pm Purchase |
2020-12-31 | 13G | SCYNEXIS, Inc. SCYX |
CAXTON CORP | 1,474,370 7.500% |
1,474,370 (New Position) |
Filing History |